BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35185048)

  • 21. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
    Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS
    Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
    Jain P; Kantarjian H; Patel K; Faderl S; Garcia-Manero G; Benjamini O; Borthakur G; Pemmaraju N; Kadia T; Daver N; Nazha A; Luthra R; Pierce S; Cortes J; Ravandi F
    Leuk Lymphoma; 2014 Jun; 55(6):1337-44. PubMed ID: 24004182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sudden death of a SARS-CoV-2 patient with NPM1 + acute myeloid leukemia mimicking acute promyelocytic leukemia.
    Giammarco S; Chiusolo P; Sica S; Rossi M; Minnella G; Zini G
    Int J Lab Hematol; 2021 Jun; 43(3):341-342. PubMed ID: 33497032
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Forghieri F; Nasillo V; Paolini A; Bettelli F; Pioli V; Giusti D; Gilioli A; Colasante C; Acquaviva G; Riva G; Barozzi P; Maffei R; Potenza L; Marasca R; Fozza C; Tagliafico E; Trenti T; Comoli P; Longo G; Luppi M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals.
    Vermeersch P; Zachee P; Brusselmans C
    Am J Hematol; 2007 Nov; 82(11):1029. PubMed ID: 17617789
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
    Hartmann L; Nadarajah N; Meggendorfer M; Höllein A; Vetro C; Kern W; Haferlach T; Haferlach C; Stengel A
    Leukemia; 2020 Mar; 34(3):811-820. PubMed ID: 31719678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two cases of follicular lymphoma with MYC gene abnormalities that presented with bone marrow necrosis.
    Miyazawa Y; Takei H; Kobayashi N; Akashi N; Sairenji Y; Sugisaki M; Naito C; Ishikawa T; Shimizu H; Ishizaki T; Yokohama A; Tsukamoto N; Yoshida Y; Matsumura N; Takayama Y; Handa H
    J Clin Exp Hematop; 2022 Dec; 62(4):208-216. PubMed ID: 36261333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of TET2 Mutation in Patients with De Novo Acute Myeloid Leukemia: A Mutation Analysis of 51 Iranian Patients.
    Chehreghani Z; Sadeghian MH; Ayatollahi H; Bagheri P; Zafari Z; Rezazadeh O; Arbab Jafari P
    Asian Pac J Cancer Prev; 2022 Mar; 23(3):803-806. PubMed ID: 35345350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational spectrum of
    Pettersson L; Holmgren B; Juliusson G; Lazarevic VL; Ehinger M
    Leuk Lymphoma; 2021 Aug; 62(8):1958-1966. PubMed ID: 33711909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
    Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
    Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
    Mattsson G; Turner SH; Cordell J; Ferguson DJ; Schuh A; Grimwade LF; Bench AJ; Weinberg OK; Marafioti T; George TI; Arber DA; Erber WN; Mason DY
    Haematologica; 2010 Apr; 95(4):670-3. PubMed ID: 20015883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.